Cytek Biosciences, Inc.CTKBNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank33
3Y CAGR-29.1%
5Y CAGR-16.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-29.1%/yr
Annual compound
5Y CAGR
-16.6%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 17.51% |
| 2024 | -0.96% |
| 2023 | 37.10% |
| 2022 | 49.13% |
| 2021 | 86.98% |
| 2020 | 43.45% |
| 2019 | 0.00% |